CY1116800T1 - Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα - Google Patents

Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα

Info

Publication number
CY1116800T1
CY1116800T1 CY20151100934T CY151100934T CY1116800T1 CY 1116800 T1 CY1116800 T1 CY 1116800T1 CY 20151100934 T CY20151100934 T CY 20151100934T CY 151100934 T CY151100934 T CY 151100934T CY 1116800 T1 CY1116800 T1 CY 1116800T1
Authority
CY
Cyprus
Prior art keywords
antibodies
compositions
methods
therapeutic antibodies
baffr
Prior art date
Application number
CY20151100934T
Other languages
English (en)
Inventor
Christoph Heusser
Julia Neugebauer
Eveline Schaadt
Stefanie Urlinger
Maximilian Woisetschlaeger
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41073830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116800(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1116800T1 publication Critical patent/CY1116800T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Αντισώματα τα οποία δεσμεύονται συγκεκριμένα στον υποδοχέα BAFF (BAFFR). Πιο συγκεκριμένα, αντισώματα που είναι ανταγωνιστές BAFFR με in vivo δραστηριότητα μείωσης των Β-κυττάρων και συνθέσεις και μεθόδους για χρήση των εν λόγω αντισωμάτων για τη θεραπεία παθολογικών διαταραχών που μπορούν να θεραπευτούν με τη θανάτωση ή τη μείωση των Β-κυττάρων, όπως είναι ο συστημικός ερυθηματώδης λύκος ή η ρευματοειδής αρθρίτιδα ή άλλες αυτοάνοσες νόσοι ή λεμφώματα, λευχαιμίες και μυελώματα.
CY20151100934T 2008-07-17 2015-10-19 Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα CY1116800T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08160671 2008-07-17
EP09160326 2009-05-15
EP09797499.2A EP2315780B8 (en) 2008-07-17 2009-07-15 Compositions and methods of use for therapeutic antibodies

Publications (1)

Publication Number Publication Date
CY1116800T1 true CY1116800T1 (el) 2017-03-15

Family

ID=41073830

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100934T CY1116800T1 (el) 2008-07-17 2015-10-19 Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα

Country Status (41)

Country Link
US (3) US8106163B2 (el)
EP (1) EP2315780B8 (el)
JP (2) JP5767109B2 (el)
KR (2) KR101314369B1 (el)
CN (1) CN102119174B (el)
AR (1) AR072749A1 (el)
AU (1) AU2009272771B2 (el)
BR (1) BRPI0915928B8 (el)
CA (1) CA2730063C (el)
CL (1) CL2011000086A1 (el)
CR (1) CR11863A (el)
CU (1) CU23878B1 (el)
CY (1) CY1116800T1 (el)
DK (1) DK2315780T3 (el)
DO (1) DOP2011000016A (el)
EA (1) EA024492B1 (el)
EC (1) ECSP11010761A (el)
ES (1) ES2547270T3 (el)
GE (1) GEP20146129B (el)
HK (1) HK1150839A1 (el)
HR (1) HRP20151227T1 (el)
HU (1) HUE025778T2 (el)
IL (1) IL210485A (el)
JO (1) JO3149B1 (el)
MA (1) MA32481B1 (el)
MX (1) MX2011000616A (el)
MY (1) MY158980A (el)
NI (1) NI201100017A (el)
NZ (1) NZ590057A (el)
PE (1) PE20110563A1 (el)
PL (1) PL2315780T3 (el)
PT (1) PT2315780E (el)
RS (1) RS54299B1 (el)
SG (1) SG193805A1 (el)
SI (1) SI2315780T1 (el)
SM (1) SMP201100010B (el)
SV (1) SV2011003807A (el)
TW (1) TWI508742B (el)
UY (1) UY31987A (el)
WO (1) WO2010007082A1 (el)
ZA (1) ZA201008952B (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009023184A2 (en) * 2007-08-10 2009-02-19 Protelix, Inc. Universal fibronectin type iii binding-domain libraries
WO2012076670A2 (en) * 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
JP2012153788A (ja) * 2011-01-25 2012-08-16 Nitto Denko Corp 光学用粘着シート
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
JP6511459B2 (ja) 2014-01-31 2019-05-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗ｂａｆｆ抗体
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3206711B1 (en) 2014-10-14 2023-05-31 Novartis AG Antibody molecules to pd-l1 and uses thereof
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
MX2018007423A (es) 2015-12-17 2018-11-09 Novartis Ag Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
HUE050632T2 (hu) 2016-02-10 2020-12-28 Novartis Ag P13K aktivitását vagy funkcióját gátló inhibitorok alkalmazása primer Sjögren-szindróma kezelésére
JP7275446B2 (ja) * 2016-06-06 2023-05-18 シティ・オブ・ホープ Ｂａｆｆ－ｒ抗体及びその使用
US11197928B2 (en) 2017-01-13 2021-12-14 Board Of Regents, The University Of Texas System Sustained production of high affinity antigen specific antibody by high dose BAFF receptor-targeting mAb-siRNA conjugate
CA3063730A1 (en) * 2017-05-24 2018-11-29 Als Therapy Development Institute Therapeutic anti-cd40 ligand antibodies
IL271194B1 (en) * 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
WO2020018922A1 (en) * 2018-07-20 2020-01-23 Teneobio, Inc. Heavy chain antibodies binding to cd19
EP3949989A4 (en) * 2019-03-29 2022-12-14 Chugai Seiyaku Kabushiki Kaisha INHIBITOR CONTAINING ANTI-IL-6 RECEPTOR ANTIBODY TO INHIBIT DETERIORATION OF BBB FUNCTION
KR20220093347A (ko) 2019-11-06 2022-07-05 노파르티스 아게 쇼그렌 증후군의 치료
CN112813099A (zh) * 2019-11-15 2021-05-18 上海细胞治疗集团有限公司 一种在活化的t细胞中具有高活性的启动子
WO2022031568A1 (en) 2020-08-04 2022-02-10 Novartis Ag Treatment of cll
EP4192869A1 (en) 2020-08-04 2023-06-14 Novartis AG Treatment of b cell malignancies
CN114149504B (zh) * 2020-09-07 2024-01-12 白先宏 Baff-r结合分子及其应用
KR20230104222A (ko) 2020-11-06 2023-07-07 노파르티스 아게 B 세포 악성종양 치료를 위한 항-cd19 작용제 및 b 세포 표적화제 병용 요법
CN115073598B (zh) * 2021-03-15 2024-02-20 盛禾(中国)生物制药有限公司 一种抗baffr抗体及其应用
CA3216063A1 (en) 2021-05-04 2022-11-10 Novartis Ag Treatment for lupus nephritis using anti-baffr antibodies
KR20240004761A (ko) 2021-05-04 2024-01-11 노파르티스 아게 항-baffr 항체를 사용한 전신 홍반성 루푸스의 치료

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51157B (sr) * 1999-08-17 2010-10-31 Biogen Idec Ma Inc. Baff receptor (bcma), imunoregulatorni agens
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
CA2595112A1 (en) * 2004-12-31 2006-07-13 Genentech, Inc. Polypeptides that bind br3 and uses thereof
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides

Also Published As

Publication number Publication date
US20120195913A1 (en) 2012-08-02
US20100021452A1 (en) 2010-01-28
ES2547270T3 (es) 2015-10-05
PL2315780T3 (pl) 2016-01-29
EA024492B1 (ru) 2016-09-30
CR11863A (es) 2011-02-11
CU20110013A7 (es) 2012-06-21
MX2011000616A (es) 2011-02-24
US8106163B2 (en) 2012-01-31
AU2009272771B2 (en) 2012-09-20
CA2730063A1 (en) 2010-01-21
CN102119174A (zh) 2011-07-06
BRPI0915928B8 (pt) 2021-05-25
US9340620B2 (en) 2016-05-17
MA32481B1 (fr) 2011-07-03
EP2315780B1 (en) 2015-08-19
US9382326B2 (en) 2016-07-05
HRP20151227T1 (hr) 2015-12-18
CL2011000086A1 (es) 2011-07-01
JP6077587B2 (ja) 2017-02-08
ECSP11010761A (es) 2011-02-28
US20120183529A1 (en) 2012-07-19
PE20110563A1 (es) 2011-08-29
UY31987A (es) 2010-02-26
DK2315780T3 (en) 2015-10-19
JP5767109B2 (ja) 2015-08-19
TWI508742B (zh) 2015-11-21
NZ590057A (en) 2012-08-31
SV2011003807A (es) 2011-03-23
MY158980A (en) 2016-11-30
NI201100017A (es) 2012-08-17
KR101545795B1 (ko) 2015-08-19
SG193805A1 (en) 2013-10-30
EP2315780B8 (en) 2015-09-23
IL210485A0 (en) 2011-03-31
SI2315780T1 (sl) 2015-11-30
SMAP201100010A (it) 2011-05-06
AR072749A1 (es) 2010-09-15
EA201100191A1 (ru) 2011-08-30
KR101314369B1 (ko) 2013-10-10
JP2015133983A (ja) 2015-07-27
BRPI0915928A2 (pt) 2015-11-03
KR20130098432A (ko) 2013-09-04
CU23878B1 (es) 2013-04-19
BRPI0915928B1 (pt) 2020-10-20
HK1150839A1 (en) 2012-01-13
CA2730063C (en) 2017-04-18
EP2315780A1 (en) 2011-05-04
AU2009272771A1 (en) 2010-01-21
JP2011527896A (ja) 2011-11-10
DOP2011000016A (es) 2011-02-15
HUE025778T2 (en) 2016-05-30
KR20110020914A (ko) 2011-03-03
WO2010007082A1 (en) 2010-01-21
RS54299B1 (en) 2016-02-29
CN102119174B (zh) 2015-01-21
PT2315780E (pt) 2015-11-30
TW201006493A (en) 2010-02-16
ZA201008952B (en) 2012-01-25
JO3149B1 (ar) 2017-09-20
GEP20146129B (en) 2014-08-11
SMP201100010B (it) 2011-09-09
IL210485A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
CY1116800T1 (el) Συνθεσεις και μεθοδοι χρησης για θεραπευτικα αντισωματα
CY1121848T1 (el) Διυποκατεστημενα οκταϋδροπυρρολο [3,4-c]πυρρολια ως ρυθμιστες υποδοχεα ορεξινης
CY1120154T1 (el) Παραγωγα πιπεριδιν-4-υλ αζετιδινης ως αναστολεις jak1
CY1119664T1 (el) Συνθεσεις και μεθοδοι αυξησης της μυϊκης αναπτυξης
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201070148A1 (ru) Соединения и способы модулирования фарнезоидного рецептора x (fxr)
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
ATE544767T1 (de) Triazoloä4,5-düpyramidinderivate und deren verwendung als purinrezeptorantagonisten
EA201591689A1 (ru) НОВЫЕ N-АЦИЛ-(3-ЗАМЕЩЕННЫЕ)-(8-ЗАМЕЩЕННЫЕ)-5,6-ДИГИДРО[1,2,4]ТРИАЗОЛО[4,3-a]ПИРАЗИНЫ КАК СЕЛЕКТИВНЫЕ АНТАГОНИСТЫ РЕЦЕПТОРА NK-3, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И МЕТОДЫ ИСПОЛЬЗОВАНИЯ ПРИ РАССТРОЙСТВАХ,ОПОСРЕДОВАННЫХ РЕЦЕПТОРОМ NK-3
EA201270720A1 (ru) Модуляторы рецептора андрогенов и их применение
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
EA201171081A1 (ru) Производные индола в качестве антагонистов рецептора crth2
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
EA200800835A1 (ru) Циклопропиламины в качестве модуляторов рецептора гистамина н
BR112013021675A2 (pt) compostos de triazolopiridina como inibidores de pim cinase
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
EA201070637A1 (ru) Соединения циклоалкилокси- и гетероциклоалкилоксипиридина как модуляторы гистаминового рецептора н